Cancer Drug Disables Toxic Alzheimer’s Protein gSAP
Posted Oct 15 2012 12:00am
The anti-cancer drug Gleevec has been shown to disable a newly
discovered key protein linked to the development of Alzheimer’s. The
protein, gSAP, stimulates production of toxic beta-amyloid which is
linked to the development of plaques in the brain typically associated
with Alzheimer’s disease .
Dr. Gen He and Dr. Paul Greengard, both of the Fisher Center for
Alzheimer’s Disease Research, have identified gamma secretase activating
protein (gSAP). They’ve found that gSAP stimulates an enzyme called
gamma secretase that is responsible for producing beta-amyloid .
The researchers also discovered that the anti-cancer drug Gleevec binds
to gSAP, preventing it from activating gamma secretase.